Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.ZEBOV and MVA-BN-Filo in Infants
NCT03929757Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2019
- Primary completion
- Aug 2022
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of zabdeno, Mvabea in Ebola virus disease (EVD), sponsored by Janssen Pharmaceutical. Started Aug 2019; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT03929757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929757.